BioSpace News Archive

Rising healthcare spending, increasing cancer cases, growing elderly population, and adoption of automated systems are the vital factors driving the growth of global tissue diagnostics market.

Rising number of cancer patients, growing awareness regarding cancer therapy, and increasing investment & government funding in product development are the key factors driving the global cancer biomarkers market growth.

Factors such as mounting costs of on-site radiologists, increasing adoption of teleradiology services across healthcare facilities for enhanced patient care, and rising prevalence of chronic ailments such as congestive heart failure as well as breast cancer are augmenting the growth of global teleradiology market.

ClearMind Biomedical has received FDA clearance for its novel neuroendoscope, the Axonpen System, for illumination and visualization of intracranial tissue and fluids, and the controlled aspiration of tissue and/or fluid during surgery. Requiring only a narrow channel of 6.5mm through the skull for insertion into the br

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Matthew Moore has joined the company as Chief Business Officer. Mr. Moore brings to Arcutis over 20 years of strategy, transaction and operations experience in the biopharmaceutic

Noctrix Health, Inc., a private medical device company, today announced it has completed a Series B financing of $17 million . The financing was co-led by Treo Ventures and OrbiMed, with participation from LivaNova PLC (NASDAQ: LIVN) and other insiders.

Proven Leader Brings Expertise in Cultivating Customer Insights to Expand Global Markets as New General Manager of Surgical

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that it has expanded its existing French distribution partnership agreement with MicroPort CRM in France to include both Spain and Portugal.

FDA also clears the Helix Genetic Health Risk App for Late-onset Alzheimer’s Disease for over-the-counter use, the first application powered by the Helix Laboratory Platform

Vagus Nerve Stimulation using Neuvana’s patented headphones showed improved speed and accuracy when learning Mandarin Chinese